Navigation Links
MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
Date:10/3/2007

Broadens late-stage product development portfolio building on lead product

candidate EcoNail in Phase 2 trial for onychomycosis

WELLESLEY HILLS, Mass., Oct. 3 /PRNewswire-FirstCall/ -- MacroChem Corporation (OTC Bulletin Board: MACM) today announced that it has exercised the option it acquired in July, 2007 to acquire exclusive worldwide license rights for drug uses of pexiganan, a novel, small peptide anti-infective for treatment of patients with mild diabetic foot infection (DFI), from Genaera Corporation.

"We believe this is a unique opportunity for MacroChem to broaden its product portfolio with a product that has already completed two Phase 3 clinical trials and that fits our strategic focus and complements our lead product candidate, EcoNail(R) for treatment of nail fungus," stated Robert J. DeLuccia, President and CEO of MacroChem. "Both drugs would treat diseases of the foot predominantly treated by the same prescribing specialists, namely podiatrists. Both EcoNail and pexiganan are potentially of interest to a larger number of physician specialists and primary care physicians. MacroChem would ultimately be seeking a partner for marketing to those groups while retaining rights to market to selected physician specialists."

In clinical trials previously conducted by Genaera, over 1000 human subjects were exposed to pexiganan without safety concerns, including 418 patients who received pexiganan in two Phase 3 clinical trials submitted in a New Drug Application to the U.S. Food and Drug Administration (FDA) in 1998. The primary clinical endpoint of one of the two Phase 3 trials was judged by the FDA to have been achieved. The other Phase 3 clinical trial, which did not meet its specified endpoint, provided strong supportive data indicative of the clinical benefit of pexiganan. At that time, difficulties with Chemistry Manufacturing & Controls (CMC) and an FDA request for one additional controlled trial precluded approval. Ma
'/>"/>

SOURCE MacroChem Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
2. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
3. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
4. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
5. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
6. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
7. Roxro Pharma’s Novel Intranasal Pain Reliever Effective, Well Tolerated in Phase 3 Study
8. Anacor Clinical Study of AN2728, a Novel Anti-Inflammatory Compound, Shows Efficacy in Psoriasis
9. Metabasis Therapeutics Presents Results of Preclinical Studies for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, at the Endocrine Societys Annual Meeting
10. Encouraging Clinical Activity of GSKs Novel Cancer Immunotherapeutic Confirmed in Phase II Study in Patients with Most Common Form of Lung Cancer
11. Clinical Data on ARIADs Novel mTOR Inhibitor, AP23573, To Be Presented at the ASCO Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... , 24 novembre 2014  Surgical Theater ... tecnologia sarà esposta durante l,apertura in data ... d,Europa, ossia la Fondazione IRCCS Istituto Neurologico ... Planner (SRP) (strumento di pianificazione chirurgica) e ... navigazione chirurgica avanzata) saranno presentati in occasione ...
(Date:11/23/2014)...  Aurobindo Pharma USA is ... mg 100-count bottles to the consumer level. The product ... Empty capsules could result in missed dose(s) ... range from no effect, short term reduction in efficacy, ... seizures) that could be life-threatening. Aurobindo Pharma ...
(Date:11/22/2014)... , 21 de noviembre de 2014  BioClinica®, ... clínicos externalizados y tecnologías eClinical, ha indicado un ... ,seguimiento inteligente, para el seguimiento basado en el ... amplía el concepto del seguimiento basado en el ... las visitas de seguimiento o cambio de los ...
Breaking Medicine Technology:La tecnologia di Surgical Theater in mostra in Italia all'apertura del centro Besta NeuroSim di Milano 2La tecnologia di Surgical Theater in mostra in Italia all'apertura del centro Besta NeuroSim di Milano 3La tecnologia di Surgical Theater in mostra in Italia all'apertura del centro Besta NeuroSim di Milano 4Aurobindo Pharma USA, Inc. Issues Voluntary Nationwide Recall of Northstar Label Gabapentin Capsules, USP 300 mg Due to Complaints of Empty Capsules 2El 'seguimiento inteligente' consigue un excelente momento 2El 'seguimiento inteligente' consigue un excelente momento 3
... ... Reportlinker.com announces that a new market research ... Fibrillation - Drug Pipeline Analysis and Market Forecasts to ... - Drug Pipeline Analysis and Market Forecasts to 2016 ...
... , , FRANKLIN, Mass. , ... Board: ECTE), a company developing the needle-free Symphony™ tCGM System ... and the Prelude™ SkinPrep System for transdermal drug delivery, announced ... Chairman and CEO, will be interviewed on " Steve Crowley ...
Cached Medicine Technology:Reportlinker Adds Atrial Fibrillation - Drug Pipeline Analysis and Market Forecasts to 2016 2Reportlinker Adds Atrial Fibrillation - Drug Pipeline Analysis and Market Forecasts to 2016 3Reportlinker Adds Atrial Fibrillation - Drug Pipeline Analysis and Market Forecasts to 2016 4Reportlinker Adds Atrial Fibrillation - Drug Pipeline Analysis and Market Forecasts to 2016 5Reportlinker Adds Atrial Fibrillation - Drug Pipeline Analysis and Market Forecasts to 2016 6Reportlinker Adds Atrial Fibrillation - Drug Pipeline Analysis and Market Forecasts to 2016 7Reportlinker Adds Atrial Fibrillation - Drug Pipeline Analysis and Market Forecasts to 2016 8Echo Therapeutics Chairman and CEO to be Interviewed on Steve Crowley's American Scene Radio Program and Featured on Money Channel Inc. 2Echo Therapeutics Chairman and CEO to be Interviewed on Steve Crowley's American Scene Radio Program and Featured on Money Channel Inc. 3Echo Therapeutics Chairman and CEO to be Interviewed on Steve Crowley's American Scene Radio Program and Featured on Money Channel Inc. 4
(Date:11/24/2014)... Olaparib functions as a chemical of the compound ... the first PARP inhibitors. Sufferers with BRCA1/2 strains may ... and are often immune to other types of melanoma ... exclusive weaknesses, as the tissues of melanoma have improved ... them to proceed splitting. This implies that medication which ...
(Date:11/24/2014)... SWAccessControl.com has recently released a new collection ... the company is a leading online supplier in the international ... available at discounted prices, up to 30% off. , “We ... This time, all of our items are offered at low ... so I have confidence in our fresh assortment. You will ...
(Date:11/24/2014)... 2014 SafeHandles™ announced that they will ... Ed Begley Jr, airing via Discovery Channel. Dates and ... a passive, non-invasive, replaceable, and affordable germ protective device. ... shrinkable sleeves and adhesives to promote hand hygiene in ... core of SafeHandles is the desire to make a ...
(Date:11/24/2014)... California (PRWEB) November 24, 2014 Dr. ... Diego Fertility Center, recently appeared on NBC to discuss egg ... Egg freezing has been trending in the news recently, with ... expensive procedure for women. , “[The companies] see ... who are on a career hot path.” Says Dr. Kettel. ...
(Date:11/23/2014)... 24, 2014 iFitDress.com, a well-known wedding dress ... evening gowns . They are now offered at deeply ... will last from now to Dec. 15. The main purpose ... All the company’s high quality items are ideal options for ... large sum of money. All its new mint cocktail dresses ...
Breaking Medicine News(10 mins):Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 2Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 3Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 4Health News:SWAccessControl.com Is Happy To Release New Range Of Magnetic Locks 2Health News:New Episode of Innovations TV Series to Feature SafeHandles™ 2Health News:Dr. Michael Kettel of San Diego Fertility Center Gives “An Inside Look at Freezing Eggs” on NBC 2Health News:Dr. Michael Kettel of San Diego Fertility Center Gives “An Inside Look at Freezing Eggs” on NBC 3Health News:Trendy Long Black Evening Gowns Now Provided By iFitDress.com 2
... effective for inoperable liver cancer. It is a year since TheraSphere was ... ... either reducing tumour size or the number of tumours. Till date, it ... cannot be treated by any other means. ,TheraSphere involves injecting ...
... given to babies with low birth weight can significantly ... die from infectious diseases. The research involved 1,154 full-term ... India, most weighing 5 1/2 pounds or less. Mothers ... months. Fifteen of the 20 who died had not ...
... starting the day with a heavy breakfast and a steaming cup ... that women who eat fried food each morning are at ... oesophageal, cancer.The best way to reduce the incidence of cancer is ... or fruit. ,Cancer of the oesophagus - the food ...
... An enzyme involved in hormone production may help explain why ... their waist have such a high risk of heart disease ... approaches to treat obesity and its complications. // ... health problems such as heart disease and diabetes, but where ...
... who use stimulants like Ritalin are not at risk ... rats suggests that stimulant treatment in childhood may blunt ... ,Many children and teens with ADHD are treated ... appear to focus patients' attention and calm behavior. But ...
... than men to suffer brain cell damage from long-term use ... be reversed if they stop taking the drug. Studies have ... MDMA, can damage nerve endings that release serotonin, a brain ... also appears to damage brain cells that transmit nerve signals. ...
Cached Medicine News:Health News:Cut down on fries 2
... Stainless steel spiral reinforced. X-ray opaque . ... Flange: The flange can be adjusted along ... of the cervical soft tissue. The lock ... is tightly connected to the shaft. Maximum ...
Fome-Cuf® tubes can breathe with the patient to provide a safe, effective, and low pressure seal throughout the ventilatory cycle....
... tracheostomy tubes are available in both neonatal and ... an uncuffed tube, but it has a cuff. ... shaft of the tube. , ,TTS™ (tight-to-shaft) ... with the insurance of a cuff, if and ...
Indications For Usage: ,Bypass upper airway obstructions, provide long term ventilation, support and/or manage tracheal/bronchial secretions....
Medicine Products: